Optimizing Treatment Strategies in Metastatic Melanoma

home / meeting-of-the-minds / optimizing-treatment-strategies-in-metastatic-melanoma

Panelists discuss the evolving treatment landscape of metastatic melanoma, highlighting 2025 clinical trial data, including RELATIVITY-047 4-year results, emerging combination strategies, and practical approaches to managing complex clinical scenarios such as high disease burden, BRAF mutations, and asymptomatic brain metastases.

RELATIVITY-047 4-Year Update: Long-Term Outcomes in Frontline Metastatic Melanoma

EP. 1: RELATIVITY-047 4-Year Update: Long-Term Outcomes in Frontline Metastatic Melanoma

Michael A. Postow, MD;Evan J. Lipson, MD;Hussein Abdul-Hassan Tawbi, MD, PhD;Megan Schollenberger, MSN, CRNP;Kathleen Madden, MSN, FNP, AOCNP, APHN;Theresa Rodgers, MPAS, PA-C
July 18th 2025

Panelists discuss evolving frontline treatment strategies for metastatic melanoma, emphasizing recent clinical updates—particularly 4-year data from the RELATIVITY-047 trial—and exploring how these findings, including the benefits of nivolumab plus relatlimab, inform real-world decision-making for complex cases like BRAF-mutant disease with high tumor burden.

Case Study: Sarah’s Journey With High-Burden BRAF V600E Melanoma

EP. 2: Case Study: Sarah’s Journey With High-Burden BRAF V600E Melanoma

Michael A. Postow, MD;Evan J. Lipson, MD;Hussein Abdul-Hassan Tawbi, MD, PhD;Megan Schollenberger, MSN, CRNP;Kathleen Madden, MSN, FNP, AOCNP, APHN;Theresa Rodgers, MPAS, PA-C
July 18th 2025

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with multiple myeloma as seen in clinical practice. The hypothetical case was co-developed by staff medical writers with Cancer Network/ONN.